It is not common to apply peritoneal medications. This delivery route is often used to manage and develop preclinical compounds, and its clinical use has been limited to chemotherapy for peritoneal tumors.
Peritotonotis is frequently present in patients with renal impairment who receive continuous mobile bypass treatment (CAPD). Peritonitis is often associated with systemic infection, so therapeutic levels of antibiotics must be achieved in both the peritoneal cavity and within the systemic circulation.
Drugs may be given orally or in order to achieve sufficient systemic levels in the hope of achieving therapeutic levels in the peritoneal cavity. Alternatively, drugs may be applied directly into the peritoneal cavity to reach systemic levels through peritoneal absorption. According to the author's knowledge, there is little clear information about the relative efficiency of these alternatives.
Peritotonotis is frequently present in patients with renal impairment who receive continuous mobile bypass treatment (CAPD). Peritonitis is often associated with systemic infection, so therapeutic levels of antibiotics must be achieved in both the peritoneal cavity and within the systemic circulation.
Drugs may be given orally or in order to achieve sufficient systemic levels in the hope of achieving therapeutic levels in the peritoneal cavity. Alternatively, drugs may be applied directly into the peritoneal cavity to reach systemic levels through peritoneal absorption. According to the author's knowledge, there is little clear information about the relative efficiency of these alternatives.
